Mesothelioma Treatment Options Beyond Chemotherapy
When chemotherapy is no longer enough, the question becomes what else exists, and this page inventories the options beyond it along with the evidence each one carries. The strongest is immunotherapy: nivolumab plus ipilimumab, two checkpoint inhibitor drugs, extended survival against platinum-pemetrexed chemotherapy in the phase 3 CheckMate 743 trial and won FDA approval in 2020 for certain unresectable cases. Older studies of interferon added to cisplatin reported response rates of 19 to 40 percent and median survival of 8.7 to 16.5 months, with epithelioid patients responding best, but interferon remains experimental. The page also covers tamoxifen, preventive radiation after biopsy, and drug combinations under study, and it explains that clinical trials are the main route to treatments not yet commercially available.
In this guide, we’ll break down some of these alternative treatments, explain what the research says, and discuss how they may shape future mesothelioma treatment.
The Role of Immunotherapy in Mesothelioma
Immunotherapy is one of the most exciting areas of cancer research today. Unlike chemotherapy, which directly attacks cancer cells, immunotherapy helps the body’s own immune system fight the cancer.
How Immunotherapy Works
The immune system is designed to detect and destroy abnormal cells. But mesothelioma, like many cancers, finds ways to evade the immune system. Immunotherapy drugs work by removing these defenses so the immune system can recognize and attack mesothelioma cells.
Checkpoint Inhibitors: Boosting the Immune Response
One of the most promising forms of immunotherapy for mesothelioma is checkpoint inhibitor therapy. These drugs block proteins that prevent the immune system from attacking cancer.
Key Checkpoint Inhibitors in Mesothelioma Research:
| Drug | Target | Notes |
|---|---|---|
| Nivolumab (Opdivo) | PD-1 | Shown to improve survival in mesothelioma. |
| Pembrolizumab (Keytruda) | PD-1 | FDA-approved for some cancers; being tested in mesothelioma. |
| Ipilimumab (Yervoy) | CTLA-4 | Often used in combination with other immunotherapies. |
In clinical trials, the combination of nivolumab and ipilimumab has extended survival in mesothelioma patients, leading to FDA approval in 2020 for some cases (Lancet). The pivotal phase 3 CheckMate 743 trial compared the duo against platinum–pemetrexed chemotherapy as first-line treatment (Lancet); both drugs now appear on the NCI list of drugs approved for mesothelioma.
Cytokine Therapy: Using the Body’s Signals to Attack Cancer
Cytokines are proteins that regulate immune responses. Researchers have tested interferons and interleukins to see if they can enhance the immune system’s ability to fight mesothelioma.
One of the most studied cytokines is alpha-interferon (IFN-α). In laboratory models, interferons have made cisplatin-based chemotherapy more effective against mesothelioma cells — for example, interferon-β showed synergistic anti-tumour effects with cisplatin and pemetrexed in laboratory studies (PLoS One).
Interferon Therapy in Mesothelioma
Interferon therapy involves using proteins that boost immune activity to help control mesothelioma growth. Alpha-interferon (IFN-α) has shown potential when combined with chemotherapy.
Key Studies on Interferon Therapy
-
France (25 Patients)
- Treatment: Weekly cisplatin (60 mg/m²) and alpha-IFN (3 million units subcutaneously)
- Results: 40% response rate; median survival 12 months
- Best responders: Patients with epithelioid mesothelioma
-
National Cancer Institute (36 Patients)
- Treatment: Cisplatin (25 mg/m²) 4 times weekly, alpha-IFN (5 million units) 3x weekly, tamoxifen (20 mg orally, twice daily)
- Results: 19% response rate; median survival 8.7 months
- Poor prognostic factors: Thrombocytosis (high platelet count) and non-epithelial mesothelioma
-
France (12 Patients)
- Treatment: Cisplatin (60 mg/m² weekly), alpha-IFN (6 million units daily for 4 days, every 4 weeks)
- Results: 1 complete response, 4 partial responses; median survival 16.5 months
These results suggest that adding interferon to chemotherapy may improve outcomes, though further trials are needed.
Other Experimental Therapies for Mesothelioma
Researchers continue to explore alternative therapies to improve survival rates and quality of life.
Tamoxifen: A Drug for Drug Resistance?
Tamoxifen, typically used for breast cancer, has been tested in mesothelioma patients to see if it can reduce chemotherapy resistance. Results have been mixed, and it is not yet widely used.
Radiotherapy as a Preventive Tool
Although radiation therapy alone does not cure mesothelioma, it has shown promise in preventing tumor spread after biopsies or surgeries.
- A French study (40 patients) tested localized radiation therapy after invasive procedures (like pleural biopsy or chest tube insertion).
- Results: None of the radiation-treated patients developed tumor seeding at the procedure site, compared to 40% of patients who did not receive radiation (Chest).
This suggested that radiotherapy could be useful in preventing local tumor recurrence — but larger follow-up trials, including the PIT trial, did not confirm the benefit, and prophylactic tract radiotherapy is no longer recommended (Lancet Oncol; Transl Lung Cancer Res).
Combining Therapies: The Future of Mesothelioma Treatment
Since no single therapy has been highly effective, researchers are exploring combination treatments to attack mesothelioma in multiple ways.
Examples of Combination Therapies Being Studied
| Therapy Combination | Goal |
|---|---|
| Chemotherapy + Immunotherapy | Boosts chemotherapy’s effectiveness by activating the immune system. |
| Radiotherapy + Surgery | Reduces tumor burden before or after surgery. |
| Checkpoint Inhibitors + Chemotherapy | Improves immune response and slows tumor growth. |
Why Combination Therapies Matter
- Mesothelioma is aggressive, so using multiple treatment approaches may slow progression.
- Some therapies reduce side effects of others (e.g., immunotherapy helping chemotherapy work better at lower doses).
- Combination approaches may extend survival compared to single-agent treatments.
The Road Ahead: What Patients Should Know
What These Findings Mean for You
- New treatments are emerging, but chemotherapy remains the standard of care.
- Clinical trials are essential—consider participating to access new therapies.
- Immunotherapy and interferon therapy show promise, but need further research.
- Combination therapies are the future—ask your oncologist about available options.
Considering Alternative Treatments?
If you or a loved one is battling mesothelioma, it’s important to discuss all available options with a specialist. Many of these new therapies are available through clinical trials, and early access to experimental treatments may improve survival.
To learn more, consider:
- Asking your doctor about ongoing clinical trials
- Exploring mesothelioma centers that specialize in experimental therapies
- Joining a patient support group for updated information and resources
The future of mesothelioma treatment is evolving, and patients today have more options than ever before. While there’s still no cure, new therapies are paving the way for better outcomes.
Frequently asked questions
What immunotherapy is approved for mesothelioma?
The article highlights nivolumab plus ipilimumab, two checkpoint inhibitors that extended survival in the phase 3 CheckMate 743 trial compared with platinum-pemetrexed chemotherapy. On that evidence regulators approved the combination in 2020 for certain unresectable cases. Whether it suits a particular patient is a question for the treating oncologist, who weighs subtype, fitness, and prior treatment.
Does interferon therapy help in mesothelioma?
Small early studies suggested benefit when alpha-interferon was added to cisplatin-based chemotherapy. In the three studies described, response rates ranged from 19 to 40 percent and median survival from roughly 8.7 to 16.5 months, with epithelioid patients responding best. The article is careful to say further trials were needed, so interferon remains experimental rather than standard care.
Can radiation stop mesothelioma spreading after a biopsy?
An early French study of 40 patients found no tumour seeding at procedure sites when localized radiation followed biopsies or chest tubes, compared with 40 percent of untreated patients. Later, bigger trials, among them the PIT study, failed to confirm that advantage, and preventive tract radiotherapy has since fallen out of favour. Radiation keeps other roles described in this guide.
Should I ask my oncologist about clinical trials?
Yes, that is the practical advice given. Many of the newer approaches described here, from immunotherapy combinations to experimental drug pairings, can be reached only through clinical trials, and the article encourages asking your oncologist about ongoing studies and seeking centers that specialize in the disease. Trials are the main route to treatments not yet commercially available.
References
- Lancet — First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): the phase 3 trial behind the 2020 FDA approval of dual checkpoint inhibition.
- National Cancer Institute — Drugs Approved for Malignant Mesothelioma: the official FDA-approved drug list for this cancer.
- PLoS One — Interferon-β produces synergistic combinatory anti-tumor effects with cisplatin or pemetrexed on mesothelioma cells: the laboratory evidence on interferon–chemotherapy synergy.
- Chest — Boutin, 1995: local radiotherapy to prevent malignant seeding along procedure tracts: the early French trial on prophylactic tract radiotherapy.
- Lancet Oncology — Prophylactic radiotherapy for the prevention of procedure-tract metastases (PIT trial) and Translational Lung Cancer Research — Is there a role for prophylactic radiotherapy to intervention tract sites?: the later trials that did not confirm the early result.